Diethylstilbestrol

Statistically significant reduction in hard clinical endpoints of TLF and TVF with DynamX; event rate flattened after one year in bioadaptor versus non-plateauing increase in DES In Left Anterior Descending (LAD) artery, bioadaptor demonstrated statistically significant 78% reduction in target lesion failure versus DES PARIS--(BUSINESS WIRE)-- Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, today announced two-year results from the BIOADAPTOR Randomized Controlled (1:1) Trial (RCT), comparing the DynamX® Coronary Bioadaptor System to standard of care Resolute OnyxTM Drug-Eluting Stent (DES) from 34 centers in Japan, Europe, and New Zealand. The results, for the first time, demonstrate significant reduction in adverse events and clinical advantage of the DynamX bioadaptor in target lesion failure (TLF) and secondary endpoint of target vessel failure (TVF) driven by sustained low event rates with DynamX compared to a two-fold increase in DES. The data were presented at a late-breaking clinical session during the EuroPCR 2024 conference in Paris. Clinical results show statistically significant benefit with DynamX bioadaptor over Resolute Onyx at two years: 65% reduction in TLF rate (1.9% versus 5.5%; p=0.046). The significant reduction in TLF was driven by low adverse events across all components of the composite endpoint with DynamX compared to DES, respectively: Cardiovascular death (0% versus 1.8%) Target vessel myocardial infarction (0.9% versus 1.9) Target lesion revascularization (0.9% versus 2.3%) 68% reduction in TVF rate (1.9% versus 6.0%; p=0.029) in DynamX compared to DES Two-year lesion subset results: 78% reduction (1.9% vs.8.7%; p=0.028) in TLF rate in left anterior descending (LAD) artery lesions treated with DynamX bioadaptor versus treatment with DES Small vessels (<2.75mm) TLF rate was 0% vs. 3.5% in DynamX versus DES, respectively Long lesions (>23mm) TLF rate was 0% vs. 2.3% in DynamX versus DES, respectively “These two-year results from the BIOADAPTOR RCT trial are very exciting—unlike anything we’ve ever seen before—and represent a new treatment category for patients living with coronary artery disease. The TLF rate curve separation validates how the bioadaptor’s unique design and mechanism of action restores the vessel viability, including the LAD vessel. It does this by restoring hemodynamic modulation validating the previously demonstrated superior imaging outcomes at one year. These data show that bioadaptor offers sustained, very low event rates across all major endpoints, making it a superior option compared to DES,” said Shigeru Saito, M.D., director of the Division of Cardiology and Catheterization Laboratory at Shonan Kamakura General Hospital in Kamakura, Japan. “The 78% magnitude of reduction in clinical events in LAD lesions is particularly important, as the artery provides 50% of a heart muscle’s blood supply and undergoes significant hemodynamic movement during every cardiac cycle. Restoring its function is clearly of significant benefit.” The DynamX bioadaptor is different from current standard of care therapies, having a novel mechanism of action designed to return vessel health through three distinct phases of adapting in the body to restore vessel biology. The locked phase establishes maximum flow lumen and restores blood flow. Unique to bioadaptor, the unlocked and separation phase of bioadaptor’s helical strands releases the vessel while maintaining the established blood flow lumen. The final phase provides adaptive dynamic support after the unlocking and separation phase to restore vessel hemodynamic modulation through restoration of pulsatility and adaptive blood flow volume and has shown evidence of plaque stabilization and regression in the lesion. “We are beyond thrilled with these findings from the BIOADAPTOR RCT,” said Motasim Sirhan, CEO of Elixir Medical. “Never before have we seen a vascular technology that addresses the limitations of existing revascularization therapies by restoring artery hemodynamic modulation and stabilizing or regressing plaque volume, as we have with DynamX bioadaptor. These exceptional patient clinical outcomes further validate that the bioadaptor is truly a transformative technology for coronary artery disease treatment.” About BIOADAPTOR RCT Trial The BIOADAPTOR RCT is an international, single-blind, randomized controlled (1:1) trial (RCT) comparing a sirolimus-eluting bioadaptor with a contemporary zotarolimus-eluting stent in 445 patients in 34 centers in Japan, Europe, and New Zealand. Both arms had large randomized multi-modality imaging subgroups of 50 patients each to document standard effectiveness benchmarks of establishing and maintaining artery flow lumen measured by percent diameter stenosis (%DS) and late lumen loss (LLL), and the new effectiveness benchmarks of restoring artery hemodynamic modulation, including pulsatility, vessel compliance, adaptive flow volume, and plaque stabilization and regression. Clinical follow-up will continue through five years. BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies involving over 9,000 patients, including INFINITY SWEDEHEART RCT (n=2400) and a global BIO-RESTORE registry with a target enrollment of up to 5,000 patients. About DynamX Coronary Bioadaptor System The DynamX bioadaptor is the first coronary implant technology designed to restore coronary artery hemodynamic modulation as demonstrated by restored vessel pulsatility, compliance, and adaptive increase in blood flow volume, and providing plaque stabilization and regression. With its unique mechanism of action (MOA), it addresses the shortcomings of drug-eluting stents and bioresorbable scaffolds (BRS) with remarkably low clinical event rates that showed a plateau between one-year and two-year clinical follow up. The DynamX Coronary Bioadaptor System is CE-marked. Not available for sale in the U.S. About Elixir Medical Elixir Medical Corporation, a privately-held company based in Milpitas, California, develops disruptive platforms to treat coronary and peripheral artery disease. Our technologies have multiple applications across the cardiovascular space capable of delivering improved clinical outcomes for millions of patients. Visit us at and on LinkedIn and X. View source version on businesswire.com: Contacts Emma Yang, Health+Commerce Email: emma@healthandcommerce.com Source: Elixir Medical View this news release online at:

With over 40 years of ophthalmology industry experience, Dr. Lindstrom will lead Surface Ophthalmics into its next stage of growth as it advances its innovative and patented proprietary portfolio for dry eye syndrome. PLEASANTON, Calif.--(BUSINESS WIRE)-- Surface Ophthalmics, a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder & Chairman. A highly acclaimed physician and surgeon in ophthalmology, Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, P.A. Dr. Lindstrom will lead in partnership with Surface’s distinguished Board of Directors including Adrienne Graves, Ph.D., (Lead Director); Perry J. Sternberg, Shelley Thunen, and J. Andy Corley. In the US alone, an estimated 38 million people have some form of DES, yet only 17 million are diagnosed and fewer still, 1.7 million, are using a prescription therapy.1,2 With its product portfolio in development, Surface seeks to address the full range of DES, from episodic to chronic by providing eye care professionals targeted therapies to treat the signs, symptoms, and underlying causes of DES, which can be naturally occurring or following ocular surgery.3 “I am honored and thrilled to lead Surface Ophthalmics into its next phase of expansion as we work to advance the company’s innovative and proprietary medicinal candidates for patients suffering from DES,” said Dr. Lindstrom. “Our solutions hold significant potential to meet existing gaps in care, and I’m eager to collaborate with our talented team to introduce these products to the market.” Surface Ophthalmics is advancing two products: Kera Sol™ Tears, an over-the-counter artificial tear solution designed for cell-compatible, short-term, fast-acting, temporary relief of burning and irritation caused by dryness of the eye. Additionally, the company is progressing the clinical program for its investigational drug, Mycosol (Surf-101), a first-in-class prescription eye drop that delivers Mycophenolate in Surface’s proprietary formulation. This combination is designed to provide sustained immunosuppressive action and mucin upregulation at the ocular surface. Richard Lindstrom, MD Dr. Richard Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989. Dr. Lindstrom has served as a researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon in the ophthalmology field. Dr. Lindstrom has served as associate director of the Minnesota Lions Eye Bank from 1987 - 2017. He is a medical advisor for several medical device and pharmaceutical manufacturers and serves on the boards of several public and privately held life sciences companies. Dr. Lindstrom previously served as president of the International Society of Refractive Surgery from 1993 to 1994, the International Intraocular Implant Society from 2002 to 2004, the International Refractive Surgery Club from 2002 to 2004, and the American Society of Cataract and Refractive Surgery from 2007 to 2008. He currently serves on the ASCRS Executive Committee and is a past chair of the ASCRS Foundation. From 1980 to 1989, he served as a professor of ophthalmology at the University of Minnesota, where he is currently an adjunct professor and foundation trustee emeritus. Dr. Lindstrom also chaired the Ophthalmology and Visual Neurosciences Foundation for three decades. About Surface Ophthalmics Surface Ophthalmics is a pioneering biopharmaceutical firm dedicated to the discovery and market introduction of novel treatments for diseases affecting the ocular surface. Our mission is to address critical unmet needs in eye care by harnessing in-depth expertise, a dynamic strategy, operational efficiency, and distinctive clinical advantages. To learn more visit and follow us on LinkedIn. References 1 2019 Dry Eye Products Market Report, Market Scope 2 Symphony Rx Data divided by DES Prevalence Study and validated with Market Scope data 3 Craig JP, et al., TFOS DEWS II Report Executive Summary, The Ocular Surface (2017)